FDA Approval for VIZIMPRO®


FDA Approval for VIZIMPRO®

On September 27, 2018 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved  VIZIMPRO®  [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. 

See the full Prescribing Information

 Read the Press Release

Powered By GrowthZone